Literature DB >> 17976521

STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output.

Geqiang Li1, Zhengqi Wang, Yi Zhang, Zizhen Kang, Eleonora Haviernikova, Yongzhi Cui, Lothar Hennighausen, Richard Moriggl, Demin Wang, William Tse, Kevin D Bunting.   

Abstract

OBJECTIVE: Signal transducer and activator of transcription 5 (STAT5) is a critical regulator of hematopoietic development and its impaired activation is associated with hematopoietic and immune cell defects. However, much of this information has been learned from knockout mice that still retain the potential for expression of STAT5 proteins that are N-terminally truncated due to alternative internal translation initiation codons. The goal of these studies was to use transplantation-based assays to analyze the degree of STAT5 deltaN activity in hematopoietic stem cells (HSC) and throughout lymphomyeloid development.
METHODS: We have directly compared E14.5 fetal liver cells from mice with potential to express STAT5ab deltaN (STAT5ab(deltaN/deltaN)) with mice completely lacking STAT5a and STAT5b (STAT5abnull/null). We have also utilized retroviral complementation of STAT5abnull/null fetal liver HSC to enforce expression of full-length STAT5a or STAT5a lacking the first 136 amino acids (STAT5a deltaN).
RESULTS: We report that STAT5 is required for HSC, lymphocyte, and erythrocyte development. We demonstrate that restored expression of STAT5a in STAT5abnull/null HSC provides a strong selective advantage, correcting T- and B-lymphocyte and erythrocyte development. Interestingly, Gr-1(+) blood cells were inversely correlated with B lymphocytes and both were normalized by STAT5a expression. In contrast, transduction of STAT5a deltaN only provided partial B-lymphocyte development.
CONCLUSIONS: These studies define the role of STAT5 in maintaining normal lymphoid vs myeloid balance during hematopoiesis and highlight a major role for the N-domain in HSC function. The platform of retroviral complementation described here will be particularly useful for future studies to subdefine the N-domain regions that are critical for hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976521      PMCID: PMC2134320          DOI: 10.1016/j.exphem.2007.08.026

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  39 in total

1.  Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.

Authors:  M Kieslinger; I Woldman; R Moriggl; J Hofmann; J C Marine; J N Ihle; H Beug; T Decker
Journal:  Genes Dev       Date:  2000-01-15       Impact factor: 11.361

2.  DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites.

Authors:  E Soldaini; S John; S Moro; J Bollenbacher; U Schindler; W J Leonard
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain.

Authors:  Claudia Mertens; Minghao Zhong; Ravi Krishnaraj; Wenxin Zou; Xiaomin Chen; James E Darnell
Journal:  Genes Dev       Date:  2006-12-15       Impact factor: 11.361

4.  STAT5 promotes multilineage hematolymphoid development in vivo through effects on early hematopoietic progenitor cells.

Authors:  Jonathan W Snow; Ninan Abraham; Melissa C Ma; Nancy W Abbey; Brian Herndier; Mark A Goldsmith
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

5.  Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

Authors:  Jennifer A Cain; Zhifu Xiang; Julie O'Neal; Friederike Kreisel; AnnaLynn Colson; Hui Luo; Lothar Hennighausen; Michael H Tomasson
Journal:  Blood       Date:  2007-01-11       Impact factor: 22.113

6.  Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.

Authors:  Kevin D Bunting; Heath L Bradley; Teresa S Hawley; Richard Moriggl; Brian P Sorrentino; James N Ihle
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

7.  Role of the Stat4 N domain in receptor proximal tyrosine phosphorylation.

Authors:  T L Murphy; E D Geissal; J D Farrar; K M Murphy
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

8.  IL-6 signaling via the STAT3/SOCS3 pathway: functional analysis of the conserved STAT3 N-domain.

Authors:  Ling Zhang; Donna B Badgwell; Jack J Bevers; Karni Schlessinger; Peter J Murray; David E Levy; Stephanie S Watowich
Journal:  Mol Cell Biochem       Date:  2006-05-23       Impact factor: 3.396

9.  Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR.

Authors:  H Dolznig; F Grebien; E M Deiner; K Stangl; A Kolbus; B Habermann; M A Kerenyi; M Kieslinger; R Moriggl; H Beug; E W Müllner
Journal:  Oncogene       Date:  2006-05-11       Impact factor: 9.867

10.  STAT5 is an ambivalent regulator of neutrophil homeostasis.

Authors:  Laurence Fiévez; Christophe Desmet; Emmanuelle Henry; Bernard Pajak; Silke Hegenbarth; Virginie Garzé; Françoise Bex; Fabrice Jaspar; Philippe Boutet; Laurent Gillet; Alain Vanderplasschen; Percy A Knolle; Oberdan Leo; Muriel Moser; Pierre Lekeux; Fabrice Bureau
Journal:  PLoS One       Date:  2007-08-15       Impact factor: 3.240

View more
  28 in total

1.  Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Authors:  Katrin Friedbichler; Marc A Kerenyi; Boris Kovacic; Geqiang Li; Andrea Hoelbl; Saliha Yahiaoui; Veronika Sexl; Ernst W Müllner; Sabine Fajmann; Sabine Cerny-Reiterer; Peter Valent; Hartmut Beug; Fabrice Gouilleux; Kevin D Bunting; Richard Moriggl
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

2.  Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.

Authors:  Yusuke Takeda; Chiaki Nakaseko; Hiroaki Tanaka; Masahiro Takeuchi; Makiko Yui; Atsunori Saraya; Satoru Miyagi; Changshan Wang; Satomi Tanaka; Chikako Ohwada; Emiko Sakaida; Naoto Yamaguchi; Koutaro Yokote; Lothar Hennighausen; Atsushi Iwama
Journal:  Br J Haematol       Date:  2011-04-15       Impact factor: 6.998

3.  Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A.

Authors:  Daisuke Yamaji; Risu Na; Yonatan Feuermann; Susanne Pechhold; Weiping Chen; Gertraud W Robinson; Lothar Hennighausen
Journal:  Genes Dev       Date:  2009-10-15       Impact factor: 11.361

4.  STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease.

Authors:  Geqiang Li; Kristy L Miskimen; Zhengqi Wang; Xiu Yan Xie; Jennifer Brenzovich; John J Ryan; William Tse; Richard Moriggl; Kevin D Bunting
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

Review 5.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.

Authors:  Lothar Hennighausen; Gertraud W Robinson
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

6.  Gab2 promotes hematopoietic stem cell maintenance and self-renewal synergistically with STAT5.

Authors:  Geqiang Li; Zhengqi Wang; Kristy L Miskimen; Yi Zhang; William Tse; Kevin D Bunting
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

7.  Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia.

Authors:  Andrea Hoelbl; Christian Schuster; Boris Kovacic; Bingmei Zhu; Mark Wickre; Maria A Hoelzl; Sabine Fajmann; Florian Grebien; Wolfgang Warsch; Gabriele Stengl; Lothar Hennighausen; Valeria Poli; Hartmut Beug; Richard Moriggl; Veronika Sexl
Journal:  EMBO Mol Med       Date:  2010-03       Impact factor: 12.137

8.  Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

Authors:  Fulu Liu; Ghada Kunter; Maxwell M Krem; William C Eades; Jennifer A Cain; Michael H Tomasson; Lothar Hennighausen; Daniel C Link
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

9.  Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation.

Authors:  Atsushi Hosui; Akiko Kimura; Daisuke Yamaji; Bing-mei Zhu; Risu Na; Lothar Hennighausen
Journal:  J Exp Med       Date:  2009-03-30       Impact factor: 14.307

10.  Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses.

Authors:  Lina Han; Albertus T J Wierenga; Marjan Rozenveld-Geugien; Kim van de Lande; Edo Vellenga; Jan Jacob Schuringa
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.